Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Current Strategies in the Management of CINV

TOP - May 2019, Vol 12, No 2 - HOPA Abstracts
Fort Worth, TX—The oncology pharmacist plays an invaluable role in the management of chemotherapy-induced nausea and vomiting (CINV). However, as the pipeline for new anticancer drugs continues to expand, the pipeline for novel antiemetics appears to be drying up, underlining the importance of the pharmacist’s knowledge regarding currently available antiemetics for patients undergoing chemotherapy, said Michael J. Berger, PharmD, BCOP, Clinical Specialty Pharmacist, The James Cancer Hospital at The Ohio State University Wexner Medical Center, Columbus, at the 2019 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference.

“Providers are going to look at you and expect you to know what to do,” said Dr Berger. It is therefore up to the pharmacist to guard against over- or underutilization of antiemetics, while also being knowledgeable of drug properties, drug interactions, clinical trial results, clinical practice guidelines, cost, and potential for patient nonadherence, as these factors all play a role in antiemetic selection.

Dr Berger provided HOPA attendees with an in-depth overview of current antiemetic guidelines, recently approved agents, and controversies surrounding the management of CINV.

Determining Emetogenic Risk

A risk assessment for CINV should be completed for each patient before the start of anticancer therapy and before any subsequent chemotherapy cycles. Prophylactic medications should be scheduled throughout the period of risk—4 days for a single-day highly emetogenic chemotherapy (HEC) regimen and 3 days for moderately emetogenic chemotherapy (MEC). Pharmacists should also have a breakthrough agent available from a different pharmacologic class, Dr Berger advised.

“CINV is much easier to prevent than it is to treat,” he said. “It’s really key to counsel our patients to make sure they understand how important it is to be compliant with their scheduled medications, and to use breakthrough the moment they start to feel nauseous.”

Determining emetogenic risk is fairly straightforward when administering single-agent chemotherapy, but when a multiagent regimen is used, it should be based on the drug in the regimen with the highest emetic risk. For example, cisplatin (high) plus etoposide (low) would be HEC, whereas oxali­platin (moderate) plus fluorouracil (5-FU) (low) plus leucovorin (minimal) would be MEC. In the case of 2 moderately emetogenic drugs (ie, an anthracycline and cyclophosphamide), the regimen should be considered HEC.

According to Dr Berger, nausea remains a more significant problem than vomiting. Many physicians and nurses think CINV is fairly well-controlled, but patient perceptions tend to be different. A 2015 HOPA survey that assessed perceptions about nausea and vomiting among patients receiving chemotherapy revealed numerous misconceptions, including the myth that nausea and vomiting indicate the chemotherapy is working, and the belief that CINV is simply to be expected. In addition, patients frequently think that as long as they are not vomiting, their CINV is being controlled.1

Current Antiemetic Guidelines

Olanzapine, an atypical antipsychotic agent, has been found to improve outcomes when added to a prophylactic regimen of a neurokinin 1 (NK1) receptor antagonist plus a serotonin (5-HT3) receptor antagonist plus dexamethasone and is now considered a standard-of-care option for patients treated with cisplatin-based and other HEC regimens, according to guidelines from the American Society of Clinical Oncology (ASCO)2 and the National Comprehensive Cancer Network (NCCN).3 These guidelines also recommend that an NK1 receptor antagonist be added to a prophylactic regimen of a 5-HT3 receptor antagonist plus dexamethasone for patients receiving carboplatin-based chemotherapy.

If a prophylactic regimen does not contain an NK1 receptor antagonist, a single dose of granisetron (Sustol) extended-release injection or intravenous (IV) palonosetron (Aloxi) are the preferred 5-HT3 receptor antagonist, per NCCN guidelines.

“And if olanzapine wasn’t used on day one, consider it your breakthrough option,” Dr Berger advised.

Recently Approved Agents

Subcutaneous granisetron extended-release injection is a new formulation that provides sustained therapeutic drug levels for >5 days; this agent is now indicated for CINV associated with MEC and anthracycline-cyclophosphamide–based chemotherapy. Oral netupitant/palonosetron (Akynzeo) and IV fosnetupitant/palonosetron (Akynzeo) are fixed-combination products containing a long-acting NK1 receptor antagonist and a long-acting 5-HT3 receptor antagonists, and are indicated for the prevention of acute and delayed CINV.

Rolapitant (Varubi), which is indicated for the prevention of acute and delayed CINV, including, but not limited to, HEC, has the longest half-life of the available NK1 receptor antagonist, and has no drug–drug interactions with dexamethasone.

Aprepitant injectable emulsion (Cinvanti) is a surfactant-free, novel formulation that appears to be better tolerated than IV fosaprepitant (Emend), and is indicated for the prevention of acute and delayed CINV associated with HEC and MEC.

“Aprepitant emulsion [can be administered via] IV push, and it causes less infusion site reactions and less hypersensitivity [than fosaprepitant],” Dr Berger noted. “So that’s a nice option.”

Controversies in Managing CINV

Controversy surrounds the optimal dose of dexamethasone, but the dose can be individualized based on patient-specific factors, concurrent medications, side effects, and chemotherapy regimen, according to Dr Berger.

More controversy surrounds carboplatin’s emetogenicity. Carboplatin area under the curve of ≥4 is currently considered HEC (according to NCCN guidelines), or a unique category of MEC (according to ASCO guidelines), and requires prophylaxis with an NK1 receptor antagonist or olanzapine.

“Carboplatin is on the upper end of the MEC spectrum,” he said.

The preferred 5-HT3 receptor antagonist when no NK1 receptor antagonist is used is granisetron extended-release injection or palonosetron. When an NK1 receptor antagonist is used, there is no preferred 5-HT3 receptor antagonist agent, yet.

“But, ASCO revised their guidelines in 2017 before granisetron extended-­release [was approved], so this could change in the future,” Dr Berger noted. As of now, there is also no preferred NK1 receptor antagonist agent.

In terms of HEC regimens, olanza­pine has been established as noninferior to an NK1 receptor antagonist regimen, and an NK1 receptor antagonist regimen plus olanzapine is better than an NK1 receptor antagonist regimen alone. The oncology community is also awaiting data on an NK1 receptor antagonist plus an olanzapine regimen, versus olanzapine alone.

The Pharmacist’s Role

According to Dr Berger, the goal for patients should always be grade 0 emesis and ≤grade 1 nausea (ie, patients are still able to eat and drink). If, in the first 24 hours of treatment, patients experience grade 1 emesis or grade 2 nausea, acute prevention should be escalated.

“If you haven’t added olanzapine or an NK1 receptor antagonist, you should,” he advised. If a patient has been adherent to their medications and experiences grade 1 emesis or grade 2 nausea in the delayed setting, escalate delayed prevention and add olanzapine or dexamethasone, or consider changing the 5-HT3 receptor antagonist and/or NK1 receptor antagonist to a longer­acting agent.

Before devising a plan for an antiemetic regimen, pharmacists should consider patient- and treatment­specific risk factors for CINV, as well as any other contributing factors for nausea and vomiting (eg, concomitant medications, disease), Dr Berger noted. They can also use the CINV toolkit offered on the HOPA website. l


  1. Hematology/Oncology Pharmacy Association. Myths and facts about CINV. Accessed April 19, 2019.
  2. Hesketh PJ, Bohlke K, Kris MG. Antiemetics: American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract. 2017;13:825-830.
  3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis. Version 1.2019. February 28, 2019. Accessed April 22, 2019.
Related Items
Gathering and Assessing Social Determinants of Health for Improved Patient Outcomes
Meg Barbor, MPH
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in Healthcare Policy
Oncology Biosimilars: 2020 Update
Meg Barbor, MPH
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Biosimilars
International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020
Meg Barbor, MPH
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Medical Marijuana
Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics
Meg Barbor, MPH
TOP - March 2020, Vol 13, No 2 published on March 11, 2020 in Biosimilars
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
Genetic Profiling and Personalized Medicine in Myelodysplastic Syndromes
Meg Barbor, MPH
TOP - January 2020, Vol 13, No 1 published on January 10, 2020 in Hematologic Cancers
Engaging Patients in Their Cancer Care Through Digital Health
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Neurofeedback Reduces Symptoms of CIPN
Meg Barbor, MPH
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in MASCC/ISOO Conference Highlights
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
The Evolving Role of Precision Medicine in Clinical Practice
Meg Barbor, MPH
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in HOPA Abstracts
Last modified: July 22, 2021